An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)

Key facts

Sponsor

Bayer

Intervention

Aflibercept (Eylea)(drug)

Enrollment

200 enrolled

Eligibility

1 years · All sexes

Timeline

2024 – 2027

Study locations (1)

• Many locations, Multiple Locations, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Retinopathy of prematurity

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07093255
  Safety, PK and PD of FLQ-101 in Premature Neonates
  FELIQS INC.
• RECRUITINGNCT06612541
  Point-of-Care Ophthalmic Diagnostic Imaging of Retinopathy of Prematurity
  Vanderbilt University Medical Center
• ENROLLING BY INVITATIONNANCT07334652
  Pain and Comfort in the Examination of Retinopathy of Prematurity
  Ataturk University
• RECRUITINGNANCT06717412
  Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy
  Wang Yusheng
• RECRUITINGNCT05558059
  Imaging Retinal Vasculature in Infant Eyes
  Duke University
• ACTIVE NOT RECRUITINGNANCT06109285
  Validation of i-ROP DL to Detect More Than Mild ROP
  Siloam Vision
• RECRUITINGNANCT06694103
  The Effect of Two Non-Pharmacological Methods on Pain During Retinopathy Examination
  Sinem Basdemir
• RECRUITINGPHASE3NCT06067958
  Intranasal Dexmedetomidine for Pain Management During Screening for Retinopathy of Prematurity
  Assaf-Harofeh Medical Center

See all trials for Retinopathy of prematurity →